Rosetta Genomics to Present at LD MICRO “Main Event” Micro-Cap Growth Conference on December 3, 2014

LD Micro Main Event Conference 2014

PRINCETON, N.J. & REHOVOT, Israel & BOSTON--()--Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that Company management will participate in the upcoming LD MICRO “Main Event” Micro-Cap Growth Conference taking place from December 2-4, 2014 in Los Angeles. Kenneth A. Berlin, President and CEO of Rosetta Genomics, will present a corporate overview on Wednesday, December 3, 2014 at 5:00 p.m. PST (8:00 p.m. EST).

Mr. Berlin’s presentation will be webcast live on the internet and can be accessed at the Investors section of the Company’s website at www.rosettagenomics.com, where it will also be archived for 90 days.

About Rosetta Genomics

Founded in 2000, Rosetta’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools and therapeutics. Rosetta currently commercializes a full range of microRNA-based molecular diagnostics. Rosetta’s cancer testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab. For more information, please visit www.rosettagenomics.com.

Rosetta Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta’s future expectations, plans and prospects, including without limitation, statements relating to Rosetta monetizing its leading microRNA platform and expertise, Rosetta developing and commercializing diagnostic tools, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta’s Annual Report on Form 20-F for the year ended December 31, 2013 as filed with the SEC. In addition, any forward-looking statements represent Rosetta’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Contacts

Rosetta Genomics:
Ken Berlin, 609-419-9000, ext. 1326
President & CEO
investors@rosettagenomics.com
or
Rosetta Genomics Investor:
LHA
Anne Marie Fields, 212-838-3777
afields@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com

Contacts

Rosetta Genomics:
Ken Berlin, 609-419-9000, ext. 1326
President & CEO
investors@rosettagenomics.com
or
Rosetta Genomics Investor:
LHA
Anne Marie Fields, 212-838-3777
afields@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com